The Henry Ford Health System has been granted a patent for a method to prevent and treat cardiovascular diseases in patients with Type 2 Diabetes Mellitus who have suffered a stroke. The method involves administering microRNA-126 containing agents. GlobalData’s report on Henry Ford Health System gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Henry Ford Health System, was a key innovation area identified from patents. Henry Ford Health System's grant share as of April 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cardiovascular disorders with microrna-126 containing exosomes
A recently granted patent (Publication Number: US11957705B2) discloses a method for treating cardiovascular disorders or diseases in individuals with Type 2 Diabetes Mellitus who have experienced a stroke. The method involves administering therapeutic amounts of exosomes containing miR-126, with the exosomes derived from CD133+ cells, specifically CD133+/KDR+ cells isolated from human umbilical cord blood cells. The concentration of miR-126 in these exosomes is highlighted to be higher compared to exosomes derived from endothelial cells or human umbilical cord blood cells.
Furthermore, the patent claims include the incorporation of miR-29b in the exosomes, with a higher concentration of miR-29b in these exosomes compared to those derived from endothelial cells or human umbilical cord blood cells. The therapeutic amount of exosomes containing miR-126 specified in the claims is at least 3×1010, with the method applicable to treating ischemic or hemorrhagic strokes, as well as heart failure and cardiomyopathy, particularly systolic heart failure denoted by a left ventricle ejection fraction of less than 40%. The patent also mentions the derivation of exosomes from endothelial cells, specifically brain endothelial cells, for the treatment method.
To know more about GlobalData’s detailed insights on Henry Ford Health System, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
